질 약물 전달의 혁신
재발성 유산 방지 및 IVF 치료의 근거
— As featured in —
환자 결과를 개선하기 위해 새롭고 혁신적인 여성 전용의 약물 전달 시스템이 필요합니다.
자세히 알아보기 about the current state of vaginal drug delivery
Calla Lily Clinical Care는 여러 가지 주목할 만한 이점을 갖는 새로운 질 약물 전달 기기의 특허를 획득했습니다.
자세히 알아보기 about the Callavid® technology and how it can improve drug delivery and patient experiences
“Callavid will be unbelievably popular with miscarriage patients as pessary leakage is the most frequent complaint, causing significant anxiety. The benefits of reducing psychological trauma, anxiety and depression are badly needed.”
Professor Siobhan Quenby
Director Biomedical Research Unit in Reproductive Health,Professor of Obstetrics University of Warwick,
Deputy Director Tommy’s National Centre for Miscarriage Research,
Calla Lily Clinical Care Medical Advisor
Issue 394, Summer 2023
The vagina’s huge medical potential has gone untapped, but not for much longer
“Calla Lily has developed a new leak-free vaginal drug delivery platform. It's simple to use (essential when patients have to administer medications themselves) and also helps to alleviate dosage anxiety and other stresses”
"NICE의 새로운 유산 관리 가이드라인 덕분에, 처음으로 우리는 이제 유산 발생률을 줄이는 데 도움이 되는 권장 약제인 질 미분화 프로게스테론을 처방할 수 있게 되었습니다. Calla Lily Clinical Care의 새로운 기기는 이전에 질 전달 프로게스테론에서 있었던 누출과 불편감 같이 환자가 겪는 문제를 해결합니다."
닥터 Stuart Lavery
UCLH 여성 건강 임상 책임자, Calla Lily 임상 진료 의학 고문
“This novel platform is of great benefit to anyone using a vaginally-delivered medication. By addressing the major issue of leakage, women can be assured the device delivers the correct dose in a convenient, tidy and less invasive fashion. It is truly a transformative device.”
Dr Kelle Moley
Former Deputy Director of Reproductive Health Technologiesat the Bill & Melinda Gates Foundation,
Calla Lily Clinical Care Medical Advisor